|
1
|
Wyss A, Hashibe M, Chuang SC, Lee YC,
Zhang ZF, Yu GP, Winn DM, Wei Q, Talamini R, Szeszenia-Dabrowska N,
et al: Cigarette, cigar, and pipe smoking and the risk of head and
neck cancers: Pooled analysis in the international head and neck
cancer epidemiology consortium. Am J Epidemiol. 178:679–690. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferris RL: Immunology and immunotherapy of
head and neck cancer. J Clin Oncol. 33:3293–3304. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kuss I, Hathaway B, Ferris RL, Gooding W
and Whiteside TL: Decreased absolute counts of T lymphocyte subsets
and their relation to disease in squamous cell carcinoma of the
head and neck. Clin Cancer Res. 10:3755–3762. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bauernhofer T, Kuss I, Henderson B, Baum
AS and Whiteside TL: Preferential apoptosis of CD56dim natural
killer cell subset in patients with cancer. Eur J Immunol.
33:119–124. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ferris RL: Progress in head and neck
cancer immunotherapy: Can tolerance and immune suppression be
reversed? ORL J Otorhinolaryngol Relat Spec. 66:332–340. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Burtness B, Harrington KJ, Greil R,
Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane
P, Bratland Å, et al: Pembrolizumab alone or with chemotherapy
versus cetuximab with chemotherapy for recurrent or metastatic
squamous cell carcinoma of the head and neck (KEYNOTE-048): A
randomised, open-label, phase 3 study. Lancet. 394:1915–1928. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ferris RL, Blumenschein G Jr, Fayette J,
Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE,
Even C, et al: Nivolumab for recurrent squamous-cell carcinoma of
the head and neck. New Engl J Med. 375:1856–1867. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pyagay P, Heroult M, Wang Q, Lehnert W,
Belden J, Liaw L, Friesel RE and Lindner V: Collagen triple helix
repeat containing 1, a novel secreted protein in injured and
diseased arteries, inhibits collagen expression and promotes cell
migration. Circ Res. 96:261–268. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Duan X, Yuan X, Yao B, Song W, Li Z,
Enhejirigala, Kong Y, Wang Y, Fu X and Huang S: The role of CTHRC1
in promotion of cutaneous wound healing. Signal Transduct Target
Ther. 7:1832022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bian Z, Miao Q, Zhong W, Zhang H, Wang Q,
Peng Y, Chen X, Guo C, Shen L, Yang F, et al: Treatment of
cholestatic fibrosis by altering gene expression of Cthrc1:
Implications for autoimmune and non-autoimmune liver disease. J
Autoimmun. 63:76–87. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Takeshita S, Fumoto T, Matsuoka K, Park
KA, Aburatani H, Kato S, Ito M and Ikeda K: Osteoclast-secreted
CTHRC1 in the coupling of bone resorption to formation. J Clin
Invest. 123:3914–3924. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Stohn JP, Wang Q, Siviski ME, Kennedy K,
Jin YR, Kacer D, DeMambro V, Liaw L, Vary CP, Rosen CJ, et al:
Cthrc1 controls adipose tissue formation, body composition, and
physical activity. Obesity (Silver Spring). 23:1633–1642. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ni SJ, Ren F, Xu M, Tan C, Weng W, Huang
Z, Sheng W and Huang D: CTHRC1 overexpression predicts poor
survival and enhances epithelial-mesenchymal transition in
colorectal cancer. Cancer Med. 7:5643–5654. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ding X, Huang R, Zhong Y, Cui N, Wang Y,
Weng J, Chen L and Zang M: CTHRC1 promotes gastric cancer
metastasis via HIF-1α/CXCR4 signaling pathway. Biomed Pharmacother.
123:1097422020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yan L, Yu J, Tan F, Ye GT, Shen ZY, Liu H,
Zhang Y, Wang JF, Zhu XJ and Li GX: SP1-mediated microRNA-520d-5p
suppresses tumor growth and metastasis in colorectal cancer by
targeting CTHRC1. Am J Cancer Res. 5:1447–1459. 2015.PubMed/NCBI
|
|
18
|
Ma MZ, Zhuang C, Yang XM, Zhang ZZ, Ma H,
Zhang WM, You H, Qin W, Gu J, Yang S, et al: CTHRC1 acts as a
prognostic factor and promotes invasiveness of gastrointestinal
stromal tumors by activating Wnt/PCP-Rho signaling. Neoplasia.
16:265–278. 278e1–e13. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hou MZ, Cheng ZQ, Shen HW, He S, Li Y, Pan
Y, Feng C, Chen X, Zhang Y, Lin M, et al: High expression of CTHRC1
promotes EMT of epithelial ovarian cancer (EOC) and is associated
with poor prognosis. Oncotarget. 6:35813–35829. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang C, Li Z, Shao F, Yang X, Feng X, Shi
S, Gao Y and He J: High expression of collagen triple helix repeat
containing 1 (CTHRC1) facilitates progression of oesophageal
squamous cell carcinoma through MAPK/MEK/ERK/FRA-1 activation. J
Exp Clin Canc Res. 36:842017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zheng M, Zhou Q, Liu X, Wang C and Liu G:
CTHRC1 overexpression promotes cervical carcinoma progression by
activating the Wnt/PCP signaling pathway. Oncol Rep. 41:1531–1538.
2019.PubMed/NCBI
|
|
22
|
Yuan RX, Bao D and Zhang Y: Linc00707
promotes cell proliferation, invasion, and migration via the
miR-30c/CTHRC1 regulatory loop in breast cancer. Eur Rev Med
Pharmaco. 24:4863–4872. 2020.PubMed/NCBI
|
|
23
|
Zhou H, Su L, Liu C, Li B, Li H, Xie Y and
Sun D: CTHRC1 may serve as a prognostic biomarker for
hepatocellular carcinoma. Onco Targets Ther. 12:7823–7831. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sial N, Ahmad M, Hussain MS, Iqbal MJ,
Hameed Y, Khan M, Abbas M, Asif R, Rehman JU, Atif M, et al: CTHRC1
expression is a novel shared diagnostic and prognostic biomarker of
survival in six different human cancer subtypes. Sci Rep.
11:198732021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bai Y, Yin K, Su T, Ji F and Zhang S:
CTHRC1 in ovarian cancer promotes M2-like polarization of
tumor-associated macrophages via regulation of the STAT6 signaling
pathway. Onco Targets Ther. 13:5743–5753. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang Z, Jensen MA and Zenklusen JC: A
practical guide to the cancer genome atlas (TCGA). Methods Mol
Biol. 1418:111–141. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rhodes DR, Kalyana-Sundaram S, Mahavisno
V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ,
Kincead-Beal C, Kulkarni P, et al: Oncomine 3.0: Genes, pathways,
and networks in a collection of 18,000 cancer gene expression
profiles. Neoplasia. 9:166–180. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li T, Fan J, Wang B, Traugh N, Chen Q, Liu
JS, Li B and Liu XS: TIMER: A web server for comprehensive analysis
of tumor-infiltrating immune cells. Cancer Res. 77:e108–e110. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and
Varambally S: UALCAN: A portal for facilitating tumor subgroup gene
expression and survival analyses. Neoplasia. 19:649–658. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Reis-Filho JS and Tutt ANJ: Triple
negative tumours: A critical review. Histopathology. 52:108–118.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shien T, Shimizu C, Seki K, Shibata T,
Hojo T, Ando M, Kohno T, Katsumata N, Akashi-Tanaka S, Kinoshita T
and Fujiwara Y: Comparison among different classification systems
regarding the pathological response of preoperative chemotherapy in
relation to the long-term outcome. Breast Cancer Res Treat.
113:307–313. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lánczky A and Győrffy B: Web-based
survival analysis tool tailored for medical research (KMplot):
Development and implementation. J Med Internet Res. 23:e276332021.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lee CE, Vincent-Chong VK, Ramanathan A,
Kallarakkal TG, Karen-Ng LP, Ghani WM, Rahman ZA, Ismail SM,
Abraham MT, Tay KK, et al: Collagen triple helix repeat
containing-1 (CTHRC1) expression in oral squamous cell carcinoma
(OSCC): Prognostic value and clinico-pathological implications. Int
J Med Sci. 12:937–945. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu GL, Sengupta PK, Jamal B, Yang HY,
Bouchie MP, Lindner V, Varelas X and Kukuruzinska MA:
N-glycosylation induces the CTHRC1 protein and drives oral cancer
cell migration. J Biol Chem. 288:20217–20227. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Scheel C, Eaton EN, Li SHJ, Chaffer CL,
Reinhardt F, Kah KJ, Bell G, Guo W, Rubin J, Richardson AL and
Weinberg RA: Paracrine and autocrine signals induce and maintain
mesenchymal and stem cell states in the breast. Cell. 145:926–940.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Weidhaas JB, Harris J, Schaue D, Chen AM,
Chin R, Axelrod R, El-Naggar AK, Singh AK, Galloway TJ, Raben D, et
al: The KRAS-variant and cetuximab response in head and neck
squamous cell cancer: A secondary analysis of a randomized clinical
trial. JAMA Oncol. 3:483–491. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Loganathan SK, Schleicher K, Malik A,
Quevedo R, Langille E, Teng K, Oh RH, Rathod B, Tsai R,
Samavarchi-Tehrani P, et al: Rare driver mutations in head and neck
squamous cell carcinomas converge on NOTCH signaling. Science.
367:1264–1269. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Oshimori N, Oristian D and Fuchs E: TGF-β
promotes heterogeneity and drug resistance in squamous cell
carcinoma. Cell. 160:963–976. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Guo B, Yan H, Li L, Yin K, Ji F and Zhang
S: Collagen triple helix repeat containing 1 (CTHRC1) activates
Integrin β3/FAK signaling and promotes metastasis in ovarian
cancer. J Ovarian Res. 10:692017. View Article : Google Scholar : PubMed/NCBI
|
